New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF) First data from post-marketing surveillance was consistent with the safety profile of OFEV from the clinical studies supporting its FDA approvalIn two separate post-hoc analyses of an open-label extension of the Phase III trials, in one analysis of OFEV treated patients, a similar decline in lung function was observed regardless of the person's level of disease severity at the start of the study while another study suggests that OFEV was effective over approximately two yearsPost-hoc analysis of the Phase III trials suggests that OFEV had a similar effect even if people reduced or held doses to manage side effects

RIDGEFIELD, Conn. and WASHINGTON, Nov. 13, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses of OFEV for the treatment of idiopathic pulmonary fibrosis (IPF) at the Pulmonary Fibrosis Foundation's PFF Summit 2015 in Washington, D.C. In 2014, OFEV became one of the first FDA-approved drug treatments for IPF, a rare and serious lung disease that causes permanent scarring of the lungs. In a post-marketing surveillance study in the United States, treatment with OFEV in the real-world clinical setting showed a safety profile consistent with that observed in clinical trials supporting its approval by the FDA. "The approval of OFEV was...